Man-made blood vessels developed by researchers at Duke University, Yale University and the tissue engineering company Humacyte appear to be both safe and more durable than commonly used synthetic versions in patients undergoing kidney dialysis, the researchers report.
The findings, published May 12 in The Lancet, resulted from a phase 2 study among 60 patients with kidney failure who required dialysis, which often requires a synthetic graft when the patient’s own blood vessel degrades from frequent needle sticks.
Such grafts, however, are prone to infection, clotting, and other complications. And alternative bioengineered grafts derived from the patient, a donor, or animal tissue have been shown to perform no better than synthetics.
The Duke and Yale research team — along with surgeons in Poland and the United States and scientists at Humacyte, which is developing the bioengineered vessel — tested a human acellular vessel, or HAV, that is manufactured to be available to patients on demand, rather than made-to-order using an individual’s own cells.
“The bioengineered blood vessel represents a critical step in tissue engineering,” said Jeffrey Lawson, M.D., Ph.D., professor of surgery and pathology at Duke and chief medical officer of Humacyte. “Because these vessels contain no living cells, patients have access to off-the-shelf engineered grafts that can be used without any waiting period associated with tailor-made products.”
Lawson and co-author Laura Niklason, M.D., Ph.D., professor of anesthesiology and biomedical engineering at Yale, are principals of Humacyte, Inc., which supported the clinical trial.
To create the vessels, the researchers first isolated vascular cells from human donors and grew them in tissue culture. They then placed the cells on a degradable scaffold shaped like a blood vessel. As the tissue grew, it was bathed in nutrients and stretched to acquire the physical properties of real blood vessels.
“After that process, which takes eight weeks, the scaffold degrades and what we have left is engineered tissue that we have grown from scratch,” Niklason said.
The final step was to wash away the cells with a special solution. The remaining “de-cellularized” tissue retains the structure of the vessel but none of the components that would cause tissue rejection.
One year after implantation, the bioengineered vessels appeared to be both safe and functional, maintaining their mechanical integrity, the researchers report. The patients also showed no sign of rejection.
While there were cases of adverse events such as clotting, the rates of those events were comparable to other dialysis grafts. Notably, the durability of the bioengineered vessels at one year was 89 percent, compared to the approximately 60-percent rate of synthetic grafts reported in previous studies.
Additionally, the researchers noted that after implantation, the bioengineered vessels had been repopulated with the patient’s own cells, so nonliving tissue became living over time.
“The fact that an implanted acellular tube becomes a living human tissue has implications for regenerative medicine in a very profound way,” Lawson said.
The Latest on: Bioengineered Blood Vessel
via Google News
The Latest on: Bioengineered Blood Vessel
- Humacyte Secures $50 Million Debt Facility with Silicon Valley Bankon April 14, 2021 at 4:34 am
DURHAM, N.C., April 14, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale ...
- Humacyte Secures $50 Million Debt Facility with Silicon Valley Bankon April 14, 2021 at 4:32 am
DURHAM, N.C., April 14, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human ... first-in-class Human ...
- Taiwanese Frog Species Found To Have Six Sex Chromosomeson April 13, 2021 at 1:06 am
A research team has bioengineered a novel adhesive patch platform that can efficiently deliver blood vessel-forming growth factors using a bio-adhesive material that is made from mussels harmless to ...
- Blood vessel formation in damaged tissues with mussel adhesive proteinon April 11, 2021 at 9:00 pm
POSTECH professor Hyung Joon Cha's research team develops a drug-delivering adhesive patch that mimics the blood vessel formation mechanism. The patch can be applied to any shape anyplace and was ...
- Blood vessel formation in damaged tissues with mussel adhesive proteinon April 11, 2021 at 5:00 pm
Recently, a research team at POSTECH has bioengineered a novel adhesive patch platform that can efficiently deliver blood vessel-forming growth factors spatiotemporally using mussel adhesive ...
- A Milestone in 3D-Printed Organson March 23, 2021 at 11:04 am
The 3D-printed constructs are biocompatible and support new blood vessel growth into the transplanted material ... One approach is fabricating lungs in the lab by combining cells with a bioengineered ...
- Humacyte CEO Dr. Laura Niklason and Alpha Healthcare CEO Rajiv Shukla to Present at CED Venture Connect 2021 Online Summiton March 23, 2021 at 4:33 am
DURHAM, N.C., March 23, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human ... a portfolio of human ...
- Bio Roundup: DIY Biohacking, PCSK9 Data, Solid Setback & Moreon March 15, 2021 at 5:00 pm
Humacyte closed a $75 million Series C round that the Research Triangle Park, NC, company will use to continue Phase 3 studies of its bioengineered blood vessels and to complete a bioprocessing ...
- 2 SPAC Stocks That Could Be 10-Baggerson March 14, 2021 at 3:21 am
The company focuses especially on human acellular vessels (HAVs). These HAVs are bioengineered blood vessels that are highly resistant to infection. So far, Humacyte has successfully completed ...
- Humacyte to Present Long-Term Follow-Up Data from Phase 2 Vascular Access Trial at Charing Cross (CX) International Symposium 2021on March 5, 2021 at 4:33 am
Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that the clinical results of five-year outcomes ...
via Bing News